Study guide

1.6 Differential Diagnosis, Indication & Referral Urgency

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

1.6 Differential Diagnosis, Indication & Referral Urgency

Key Takeaways Explain This Topic AI

A genetics differential weighs chromosomal, single-gene, multifactorial, teratogenic/infectious, and maternal metabolic explanations against the timed clinical data.

Indication for genetic counseling/testing should be explicit, evidence-linked, and matched to the question being asked (diagnostic, carrier, prenatal, predictive).

Referral urgency is driven by pregnancy gestational age, testing windows (NIPT, CVS, amniocentesis, anatomy survey follow-up), progressive disease, and time-sensitive reproductive decisions.

Appropriateness means the right service intensity: GC visit, MFM, medical genetics, urgent inpatient consult, or deferral with clear safety-net follow-up.

CGC exam items often hinge on triage: recognizing when delay harms options versus when immediate invasive testing is not the first appropriate step.

Last updated: August 2026

After history and exposure assessment, Domain 1A asks you to build a differential , state a coherent indication , and judge appropriateness and urgency of referral . These skills are application-heavy on the CGC: candidates must choose what happens next, not only name a syndrome.

Building a genetics-informed differential

A practical differential for congenital or developmental presentations usually includes several buckets:

Bucket Examples of clues Typical next evaluations

Chromosomal / genomic copy-number Multiple anomalies, IUGR + anomalies, ID + malformations Karyotype (if indicated), chromosomal microarray, sometimes FISH

Single-gene / syndromic Recognizable pattern, positive family history, consanguinity, progressive course Targeted gene test, panel, exome/genome with pretest counseling

Multifactorial / isolated anomaly Single common malformation, empiric recurrence pattern Anomaly-specific workup; recurrence risk counseling; selective genetic testing

Teratogenic / infectious Timed exposure or maternal infection matching phenotype Exposure counseling, infectious labs, MFM imaging; genetics still often involved

Maternal metabolic Maternal PKU, poorly controlled diabetes Optimize maternal management; anomaly evaluation; clarify mechanism to family

Non-genetic medical mimics Hypoxic injury, extreme prematurity complications, trauma Avoid over-calling a hereditary syndrome; document rationale

How to rank the differential

Match phenotype to pattern — Is this a known teratogen embryopathy, a classic aneuploidy pattern, or an isolated multifactorial defect?

Use timing — Anomaly onset and exposure dates support or weaken buckets.

Use base rates and red flags — Multiple major anomalies raise chromosomal/syndromic probability; a single soft marker after reassuring screening may not.

Keep more than one bucket open when data are incomplete — CMV and a chromosomal disorder can coexist; diabetes does not exclude trisomy.

State what would change management — Differentials should drive tests and referrals, not become endless lists.

Scenario: overlapping buckets

Fetus at 20 weeks with VSD, clenched hands, and growth restriction. Differential includes trisomy 18, other chromosomal imbalance, single-gene syndromes, and less likely isolated multifactorial CHD. If history also shows first-trimester valproate, NTD risk rises for future counseling, but the current phenotype is not explained by valproate alone—urgent prenatal genetic evaluation and diagnostic testing discussion remain appropriate.

Indication: make the "why" explicit

An indication is the clinically justified reason for genetic counseling and/or a specific test. Strong indications are specific:

"Prenatal counseling for fetal omphalocele and cardiac defect at 18w3d; discuss microarray/karyotype via amniocentesis vs further imaging and screening limitations."

"Pediatric counseling for developmental delay and congenital anomalies; review CMA and Fragile X as first-tier considerations."

"Maternal isotretinoin exposure from 4–6 weeks by LMP; teratogen risk counseling and coordinated MFM referral."

Weak indications are vague: "genetic counseling for anxiety," "patient wants all the genes," or "abnormal NIPT" without stating which condition and what confirmatory pathway is needed.

Match indication to test purpose :

Diagnostic — explain a present phenotype.

Screening — refine risk in an asymptomatic or low-suspicion setting.

Carrier — reproductive risk for recessive/X-linked disease.

Predictive/presymptomatic — future disease risk in an asymptomatic person (needs extra psychosocial and consent rigor).

Prenatal — fetal risk assessment under gestational time pressure.

Inappropriate indication examples include ordering predictive Huntington testing for a minor without meeting professional guidelines, or using NIPT as a diagnostic test after a high-risk ultrasound without offering diagnostic confirmation counseling.

Appropriateness of referral

Appropriateness means the right clinician, setting, and intensity:

Genetic counselor visit for risk assessment, education, test selection, and psychosocial support.

Medical geneticist for complex dysmorphology, management of rare syndromes, or exam-based diagnosis.

Maternal–fetal medicine for anomalous fetuses, teratogen exposures needing obstetric imaging, and procedure access.

Specialty clinics (cancer genetics, metabolic, cardiogenetics) when phenotype maps there.

Emergency/inpatient genetics pathways for neonates with critical congenital anomalies or metabolic crises.

Inappropriate use includes routing every advanced maternal age patient to an urgent same-day invasive procedure without counseling on screening options, or delaying a 12-week high-risk exposure consult until postpartum "when there is more time."

Urgency and time-sensitive windows

Prenatal genetics is paced by the calendar. Urgency escalates when delay will eliminate options or information.

Situation Why urgent Typical time pressure

Ongoing pregnancy with major fetal anomalies Diagnostic testing and reproductive decisions are GA-dependent Anatomy findings often ~18–22 weeks; local termination limits vary

Positive NIPT / screening Needs prompt counseling about confirmatory diagnostic testing Avoid waiting weeks without a plan

CVS vs amniocentesis timing Procedure windows differ CVS earlier; amnio later; both need counseling lead time

Teratogen exposure in first trimester Dating, risk counseling, early ultrasound planning Embryonic period already passing

Progressive genetic disease / neonatal hypotonia with metabolic concern Diagnostic delay can miss treatable conditions Hours–days, not months

Cancer genetics before risk-reducing surgery or systemic therapy timing Results may change surgical plan Coordinate with oncology dates

Triage framework for CGC-style items

Ask four questions:

Is there an ongoing pregnancy ? If yes, gestational age becomes a vital sign for the referral.

Will a delay of days/weeks close a testing or decision window ?

Is the phenotype stable outpatient or critically evolving ?

Does the family understand options well enough to wait, or do they need same-week counseling to prevent uninformed decisions?

Scenario: urgency done right

A client at 16 weeks has NIPT positive for trisomy 13 and an ultrasound with holoprosencephaly. Appropriate urgency: rapid GC/MFM counseling, discussion of diagnostic confirmation (CVS if still timely vs amniocentesis), and support for time-sensitive decisions. Inappropriate: reassurance that "NIPT is diagnostic, no further testing needed," or scheduling routine counseling in eight weeks.

Scenario: urgency overcalled

A healthy 29-year-old at 9 weeks with no exposures requests counseling solely because a coworker had a child with Down syndrome. Appropriate: offer routine prenatal genetic counseling and screening education. Inappropriate: same-day amniocentesis without indication, or labeling the case as emergent teratogen exposure.

Communication that supports triage

When you refer or accept a referral:

State the differential top items in plain language.

Name the indication for today's visit and any recommended test.

Explain what is urgent and why (window language, not fear language).

Document follow-up ownership (who calls the lab, who schedules amnio, when results return).

Avoid dumping undifferentiated "rule out genetic disease" on another service without clinical framing.

Exam traps

Collapsing differential to a single favorite syndrome despite conflicting exposure history.

Treating screening results as diagnostic confirmation.

Missing pregnancy time sensitivity (especially CVS/amnio/NIPT/anatomy follow-up).

Equating "referral to genetics" with "order the largest panel today."

Under-triaging neonatal metabolic/critical anomaly cases or over-triaging low-risk anxiety-only consults.

Forgetting that appropriateness includes psychosocial readiness for predictive testing, not only medical acuity.

Integration across Domain 1A

Clinical information work is a sequence: elicit medical/pregnancy history → classify teratogens and non-genetic risks → synthesize a differential with a clear indication → route with appropriate urgency. Candidates who memorize syndrome lists but cannot triage a 19-week anomalous fetus or a first-trimester isotretinoin exposure will miss Domain 1A application items. Practice saying aloud, for each vignette: What else could this be? What exactly are we evaluating? How soon must we act?